August 15, 2017 07:30 AM EDTUpdated 12:11 PM
Bioregnum
Opinion

Trump's re­newed broad­sides on drug pric­ing did­n't even dent bio­phar­ma this time

Late Mon­day Pres­i­dent Don­ald Trump took his sec­ond shot at Mer­ck CEO Ken Fra­zier. Clear­ly still ran­kled by Fra­zier’s de­ci­sion to re­sign from Trump’ …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

FDA ap­proves Mod­er­na’s next-gen Covid vac­cine, with lim­its on most healthy peo­ple

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

Gilead, Mer­ck re­veal 'prac­tice-chang­ing' da­ta for Trodelvy-Keytru­da com­bo in ag­gres­sive breast can­cer

Arv­inas, Pfiz­er's PRO­TAC in breast can­cer no bet­ter than oral SERDs

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times